These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 2721888)
1. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers]. Geyer H; Schwörer D; Pfleiderer A Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888 [TBL] [Abstract][Full Text] [Related]
2. [Determination of the SCC antigen in the serum of patients with cervical cancer]. Crombach G; Würz H; Bolte A Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):439-45. PubMed ID: 3623046 [TBL] [Abstract][Full Text] [Related]
3. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix]. Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H Geburtshilfe Frauenheilkd; 1989 Jul; 49(7):625-9. PubMed ID: 2777050 [TBL] [Abstract][Full Text] [Related]
4. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)]. Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197 [TBL] [Abstract][Full Text] [Related]
5. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC). Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591 [TBL] [Abstract][Full Text] [Related]
6. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Gadducci A; Tana R; Cosio S; Genazzani AR Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182 [TBL] [Abstract][Full Text] [Related]
7. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225 [TBL] [Abstract][Full Text] [Related]
8. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Tsai SC; Kao CH; Wang SJ Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143 [TBL] [Abstract][Full Text] [Related]
10. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720 [TBL] [Abstract][Full Text] [Related]
12. [The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma]. Zakrzewska I Pol Merkur Lekarski; 2001 Jan; 10(55):21-3. PubMed ID: 11320545 [TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Bolli JA; Doering DL; Bosscher JR; Day TG; Rao CV; Owens K; Kelly B; Goldsmith J Gynecol Oncol; 1994 Nov; 55(2):169-73. PubMed ID: 7959279 [TBL] [Abstract][Full Text] [Related]
14. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
15. [Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck]. Koch T; Eiffert H; Spindler MB HNO; 1989 Nov; 37(11):454-9. PubMed ID: 2584067 [TBL] [Abstract][Full Text] [Related]
16. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma. Meier W; Stieber P; Hasholzner U; Baumgartner L; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2959-62. PubMed ID: 9329575 [TBL] [Abstract][Full Text] [Related]
18. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097 [TBL] [Abstract][Full Text] [Related]
19. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Micke O; Prott FJ; Schäfer U; Tangerding S; Pötter R; Willich N Anticancer Res; 2000; 20(6D):5113-5. PubMed ID: 11326679 [TBL] [Abstract][Full Text] [Related]
20. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]